Catalent Biologics to expand in Madison
With the help of up to $1.3 million in state tax credits, Catalent Biologics’ cell line development and biomanufacturing site in Madison will expand with a $75 million investment that is expected to create at least 145 new jobs by the end of 2021.
The expansion was announced by Gov. Tony Evers and company officials. The Wisconsin Economic Development Corp. (WEDC) will support the project by authorizing the state income tax credits over the next three years. The actual amount of tax credits Catalent will receive is contingent upon the number of jobs created and the amount of capital investment during that period.
Catalent Inc., headquartered in Somerset, New Jersey, is a global provider of advanced-delivery technologies and development and manufacturing solutions for drugs, biologics, gene therapies, and consumer health products.
Madison is one of more than 35 Catalent facilities across five continents, 13 of which are in the U.S. With the buildout of two new biomanufacturing suites, mammalian cell culture capacity will be increased at the site. The expansion, which will add approximately 60,000 square feet to the existing facility, will boost clinical and commercial production at the 2,000- or 4,000-liter batch scale and more than double Catalent’s commercial biomanufacturing capacity.
In addition to the 145 jobs expected to be created by Catalent, an economic modeling study by WEDC estimates the project could indirectly generate 206 additional jobs in the Greater Madison region. The 351 total new jobs are projected to generate $804,617 in annual state income taxes.